Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
High normal blood pressure, also called prehypertension, is a significant problem. High uric acid in the blood, the same thing that causes gout, may cause higher blood pressures. The investigators plan to monitor the effects of the drug febuxostat(trade name Uloric) on blood pressure and stiffness of the main blood vessels and see if lowering uric acid has any effect.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Febuxostat | Active Comparator |
| |
| Placebo | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Febuxostat | Drug | 80mg PO daily for 8 weeks |
|
| Measure | Description | Time Frame |
|---|---|---|
| Changes in 24 Hour Blood Pressure | 8 weeks | |
| Changes in Pulse Wave Velocity | 8 weeks |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Daniel O'Connor, UCSD | UCSD | Principal Investigator |
| Jason T. Davis, M.D. | University of California, San Diego | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Univerisity Of California San Diego | San Diego | California | 92037 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 32877573 | Derived | Gois PHF, Souza ERM. Pharmacotherapy for hyperuricaemia in hypertensive patients. Cochrane Database Syst Rev. 2020 Sep 2;9(9):CD008652. doi: 10.1002/14651858.CD008652.pub4. |
Not provided
Not provided
The Principal Investigator for this study has passed away and the results data is not available.
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Febuxostat | Febuxostat: 80mg PO daily for 8 weeks |
| FG001 | Placebo | Febuxostat: 80mg PO daily for 8 weeks |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
The Principal Investigator for this study has passed away and the results data is not available.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Febuxostat | Febuxostat: 80mg PO daily for 8 weeks |
| BG001 | Placebo | Febuxostat: 80mg PO daily for 8 weeks |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Changes in 24 Hour Blood Pressure | The Principal Investigator for this study has passed away and the results data is not available. | Posted | 8 weeks |
|
|
Not provided
The Principal Investigator for this study has passed away and the results data is not available.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Febuxostat | Febuxostat: 80mg PO daily for 8 weeks | 0 |
Not provided
Not provided
The Principal Investigator for this study has passed away and the results data is not available.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Department of Medicine | UCSD | (858) 552-8585 |
Not provided
| ID | Term |
|---|---|
| D058246 | Prehypertension |
| D006073 | Gout |
| D006973 | Hypertension |
| ID | Term |
|---|---|
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D001168 | Arthritis |
| D007592 | Joint Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000069465 | Febuxostat |
| ID | Term |
|---|---|
| D013844 | Thiazoles |
| D013457 | Sulfur Compounds |
| D009930 | Organic Chemicals |
| D001393 | Azoles |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| BG002 |
| Total |
Total of all reporting groups |
|
| Sex: Female, Male |
|
| Primary | Changes in Pulse Wave Velocity | The Principal Investigator for this study has passed away and the results data is not available. | Posted | 8 weeks |
|
|
| 0 |
| 0 |
| 0 |
| 0 |
| 0 |
| EG001 | Placebo | Febuxostat: 80mg PO daily for 8 weeks | 0 | 0 | 0 | 0 | 0 | 0 |
Not provided
Not provided
Not provided
| D009140 |
| Musculoskeletal Diseases |
| D000070657 | Crystal Arthropathies |
| D012216 | Rheumatic Diseases |
| D011686 | Purine-Pyrimidine Metabolism, Inborn Errors |
| D008661 | Metabolism, Inborn Errors |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D006573 |
| Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |